雄激素受体AR)在高PSA前列腺增生和前列腺癌组织中的表达.docVIP

雄激素受体(AR)在高PSA前列腺增生和前列腺癌组织中的表达 　　作者： 王荣海,杨明山 作者单位：山东大学医学院， 济南 250012 　　【摘要】 目的 探讨雄激素受体(AR)在前列腺特异性抗原高的良性前列腺增生(BPH)组织和前列腺癌(PCa)组织中表达的意义。 方法 采用免疫组化和RTPCR法研究AR在32例前列腺特异性抗原(PSA)≥10?ng/mL的BPH(简称高PSA组)、40例PCa组织中表达的情况;32例PSA10?ng/mL的BPH(简称低PSA组)组织为对照组。 结果 低PSA组、高PSA组、PCa组AR表达的阳性率分别为84.38%、93.75%、65.00%,相互比较,差异均有统计学意义(P0.05)。AR在高PSA组上皮、间质组织中的表达高于低PSA组和PCa组织(P0.05)。高分化癌、中分化癌、低分化癌的AR表达的阳性率分别为66.67%、55.56%、30.00%,高、中分化癌的AR表达的阳性率比低分化癌高(P0.05)。早期前列腺癌的AR表达阳性率(68.75%)比晚期前列腺癌(41.67%)高(P0.05)。早期前列腺癌的AR mRNA表达量比晚期前列腺癌高(P0.05);高、中分化癌的AR mRNA表达量比低分化癌高(P0.05)。 结论 AR在高PSA组前列腺增生组织中表达增高,提示其在前列腺增生中的过表达可能是PSA增高的又一因素。AR的表达与肿瘤分级、分期相关。 　　【关键词】 前列腺增生;前列腺肿瘤;雄激素受体;前列腺特异性抗原 　　High PSA value and prostatic cancer 　　WANG Ronghai1, YANG Mingshan2 　　(1. School of Medicine, Shandong University, Jinan 250012, China; 2. Department of Urology, 　　Shandong Tumor Hospital, Jinan 250117, China) 　　Abstract: Objective To investigate the expressions of androgen receptor (AR) in benign prostatic hyperplasia (BPH) with high PSA value and prostatic cancer(PCa) tissues and its clinical significance. Methods AR expressions were determined in 32 human prostatic hyperplasia tissue specimens(PSA≥10?ng/mL group)(the high PSA group) and 40 prostatic cancer tissues by immunohistochemical and RTPCR methods. 32 human prostatic hyperplasia tissue specimens(PSA10?ng/mL group)(the low PSA group) served as the control group. Results The positive staining rates of AR in the high PSA group, the low PSA group and the PCa group were respectively 93.75%, 84.38% and 65.00%(P0.05). Positive expressions of AR were much higher in epithelial and mysenchymal tissues of the high PSA group than in the low PSA group and the PCa group(P0.05). The AR expression was significantly higher in well (66.67%) or moderately (55.56%) differentiated adenocarcinoma than that in poorly differentiated tumors (30.00%)(P0.05), and it was higher in tumors at early stages (68.75%) than in tumors at advanced stages (41.67%)(P0.0